<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37171519</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Clinical usefulness of anti-nuclear antibody in childhood: real-world experience at a tertiary care center : Usefulness of ANA in pediatric autoimmune diseases.</ArticleTitle><Pagination><StartPage>3325</StartPage><EndPage>3335</EndPage><MedlinePgn>3325-3335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-023-05017-w</ELocationID><Abstract><AbstractText>We evaluated the reasons for requesting anti-nuclear antibody (ANA) analysis in clinical practice at a tertiary center and the performance of ANA in pediatric autoimmune diseases. Patients under 18&#xa0;years of age who underwent ANA testing for various symptoms between 2013 and 2017 were included. We retrieved data from medical records, including demographic and clinical characteristics, diagnoses, ANA results, titers, and staining patterns. The performance assessment tools were calculated according to the ANA titer for autoimmune diseases. Risk factors for autoimmune diseases in ANA-positive patients were evaluated using logistic regression analysis. Changes in ANA titer and seroconversion were evaluated using repeated ANA analyses. A total of 3812 patients underwent ANA. Medical records of 3320 patients were obtained. The rate of ANA positivity was 27.4%. ANA was requested most frequently because of musculoskeletal findings in 1355 patients (40.8%). Juvenile idiopathic arthritis (n&#x2009;=&#x2009;174, 20.2%) was the most common diagnosis in ANA-positive patients, followed by systemic lupus erythematosus (n&#x2009;=&#x2009;52, 6%). For autoimmune diseases, a titer of&#x2009;&#x2265;&#x2009;1:100, a sensitivity of 40.1%, and a specificity of 77.1% were observed. At a titer&#x2009;&#x2265;&#x2009;1:1000, the sensitivity and specificity were 24.1% and 89%, respectively. Homogeneous staining was an additional risk factor for autoimmune diseases in ANA-positive patients by multivariate logistic regression analysis (OR [95% CI]: 4.562 [3.076-6.766], p&#x2009;&lt;&#x2009;0.001). &#xa0; &#xa0;Conclusion: Our results revealed that the performance of the ANA test in diagnosing autoimmune diseases in pediatric clinical practice was poor. Therefore, clinical findings should be carefully evaluated before ANA testing is performed. What is Known: &#x2022; ANA can be detected in systemic autoimmune rheumatic diseases. &#x2022; The diagnostic role of ANA is controversial, especially in childhood. What is New: &#x2022; One in four patients who requested the ANA test had an autoimmune disease. &#x2022; Less than half of patients with an autoimmune disease had ANA positivity.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#x15e;ahin</LastName><ForeName>Nihal</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2122-6952</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Rheumatology, Kocaeli University, Kocaeli University Research and Application Hospital Umuttepe, Campus 41380, &#x130;zmit, Kocaeli, Turkey. nihal_sahin41@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#x131;saarslan</LastName><ForeName>Ay&#x15f;enur Pa&#xe7;</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-1800-9922</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Rheumatology, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;i&#xe7;ek</LastName><ForeName>S&#xfc;meyra &#xd6;zdemir</ForeName><Initials>S&#xd6;</Initials><Identifier Source="ORCID">0000-0002-3290-4413</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Kayseri City Hospital, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#x131;narba&#x15f;&#x131;</LastName><ForeName>Ay&#x15f;e Seda</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-2443-4378</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Nephrology, Diyarbak&#x131;r Pediatric Hospital, Diyarbak&#x131;r, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nay</LastName><ForeName>Neslihan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0995-8501</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Nephrology, Kayseri City Hospital, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yel</LastName><ForeName>Sibel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5707-1633</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Nephrology, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dursun</LastName><ForeName>&#x130;smail</ForeName><Initials>&#x130;</Initials><Identifier Source="ORCID">0000-0002-0191-4344</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Nephrology, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poyrazo&#x11f;lu</LastName><ForeName>Muammer Hakan</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-5142-8432</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Nephrology and Division of Pediatric Rheumatology, Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;&#x15f;&#xfc;nsel</LastName><ForeName>Ruhan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0599-7199</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Nephrology and Rheumatology, Yeditepe Univesity, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001171" MajorTopicYN="Y">Arthritis, Juvenile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-nuclear antibody</Keyword><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">Diagnostic marker</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword><Keyword MajorTopicYN="N">Rheumatology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37171519</ArticleId><ArticleId IdType="doi">10.1007/s00431-023-05017-w</ArticleId><ArticleId IdType="pii">10.1007/s00431-023-05017-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holborow EJ, Weir DM, Johnson GD (1957) A Serum Factor in Lupus Erythematosus with Affinity for Tissue Nuclei. Br Med J 2:732. https://doi.org/10.1136/BMJ.2.5047.732</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ.2.5047.732</ArticleId><ArticleId IdType="pubmed">13460368</ArticleId><ArticleId IdType="pmc">1962253</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins WC, Holman HR, Deicher H, Kunkel HG (1957) Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 96:575&#x2013;579. https://doi.org/10.3181/00379727-96-23545</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-96-23545</ArticleId><ArticleId IdType="pubmed">13505796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling M, Murali M (2019) Antinuclear Antibody Tests. Clin Lab Med 39:513&#x2013;524. https://doi.org/10.1016/J.CLL.2019.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLL.2019.07.001</ArticleId><ArticleId IdType="pubmed">31668266</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Rheumatology Position Statement Subject: Methodology of Testing for Antinuclear Antibodies. Available online: https://www.rheumatology.org/Practice/Clinical/Position/Position_Statements/ . Accessed 3 Feb 2022</Citation></Reference><Reference><Citation>Fitch-Rogalsky C, Steber W, Mahler M, Lupton T, Martin L, Barr SG, Mosher DP, Wick J, Fritzler MJ (2014) Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 9:e93812. https://doi.org/10.1371/JOURNAL.PONE.0093812</Citation></Reference><Reference><Citation>P&#xe9;rez D, Gilburd B, Cabrera-Marante &#xd3; et al (2018) Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. Clin Chem Lab Med 56:1771&#x2013;1777. https://doi.org/10.1515/CCLM-2017-0241</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM-2017-0241</ArticleId><ArticleId IdType="pubmed">28628475</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers EC, Monrad SU, Warren JS, Solano M, Schnaas L, Hernandez-Avila M, Tellez-Rojo MM, Hu H (2016) Antinuclear antibody prevalence in a general pediatric cohort from Mexico City: discordance between immunofluorescence and multiplex assays. Clin Epidemiol 9:1&#x2013;8. https://doi.org/10.2147/CLEP.S121632</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S121632</ArticleId><ArticleId IdType="pubmed">28053555</ArticleId><ArticleId IdType="pmc">5192054</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YP, Wang CG, Liu X et al (2014) The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study. Curr Ther Res Clin Exp 76:116&#x2013;119. https://doi.org/10.1016/J.CURTHERES.2014.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CURTHERES.2014.06.004</ArticleId><ArticleId IdType="pubmed">25473438</ArticleId><ArticleId IdType="pmc">4245690</ArticleId></ArticleIdList></Reference><Reference><Citation>Racoubian E, Zubaid RM, Shareef MA, Almawi WY (2016) Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008&#x2013;2015: a cross-sectional study involving 10,814 subjects. Rheumatol Int 36:1231&#x2013;1236. https://doi.org/10.1007/S00296-016-3533-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00296-016-3533-0</ArticleId><ArticleId IdType="pubmed">27432022</ArticleId></ArticleIdList></Reference><Reference><Citation>Afman I, Cronj&#xe9; H, Joubert G, Badenhorst P, Schoon M (2003) Antinuclear antibody testing in obstetric patients. S Afr Med J 93:932&#x2013;937</Citation><ArticleIdList><ArticleId IdType="pubmed">14750494</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Chan EKL, Ho LA et al (2012) Prevalence and Sociodemographic Correlates of Antinuclear Antibodies In the United States. Arthritis Rheum 64:2319. https://doi.org/10.1002/ART.34380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.34380</ArticleId><ArticleId IdType="pubmed">22237992</ArticleId><ArticleId IdType="pmc">3330150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruner BF, Guthridge JM, Lu R et al (2012) Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of SLE patients and family members $watermark-text $watermark-text $watermark-text. Arthritis Rheum 64:3677&#x2013;3686. https://doi.org/10.1002/art.34651</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34651</ArticleId><ArticleId IdType="pubmed">23112091</ArticleId><ArticleId IdType="pmc">3490432</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeles AM, Abeles M (2013) The Clinical Utility of a Positive Antinuclear Antibody Test Result. Am J Med 126:342&#x2013;348. https://doi.org/10.1016/J.AMJMED.2012.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AMJMED.2012.09.014</ArticleId><ArticleId IdType="pubmed">23395534</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo AL, Le S, Ong J, Connelly K, Ojaimi S, Nim H, Morand EF, Leech M (2020) Utility of repeated antinuclear antibody tests: a retrospective database study. Lancet Rheumatol 2:412&#x2013;417. https://doi.org/10.1016/S2665-9913(20)30084-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30084-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Akikusa J, Choo S (2021) Laboratory investigations. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC (eds) Textbook of Pediatric Rheumatology, 8th edn. Elsevier, Philadelphia, PA, pp 127&#x2013;142</Citation></Reference><Reference><Citation>Wang KY, Yang YH, Chuang YH, Chan PJ, Yu HH, Lee JH, Wang LC, Chiang BL (2011) The initial manifestations and final diagnosis of patients with high and low titers of antinuclear antibodies after 6 months of follow-up. J Microbiol Immunol Infect 44:222&#x2013;228. https://doi.org/10.1016/J.JMII.2011.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JMII.2011.01.019</ArticleId><ArticleId IdType="pubmed">21524618</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslak F, Yildiz M, Altun I et al (2021) Anti-nuclear antibody testing in children: How much is really necessary? Pediatr Int 63:1020&#x2013;1025. https://doi.org/10.1111/PED.14592</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/PED.14592</ArticleId><ArticleId IdType="pubmed">33411356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayg&#xfc;n E, Kelesoglu FM, Dogdu G et al (2019) Antinuclear antibody testing in a Turkish pediatrics clinic: is it always necessary? Pan Afr Med J 32:181. https://doi.org/10.11604/PAMJ.2019.32.181.13793</Citation></Reference><Reference><Citation>Correll CK, Spector LG, Zhang L, Binstadt BA, Vehe RK (2016) Use of rheumatology laboratory studies among primary pediatricians. Clin Pediatr (Phila) 55:1279. https://doi.org/10.1177/0009922815624902</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0009922815624902</ArticleId><ArticleId IdType="pubmed">26755273</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390&#x2013;392</Citation><ArticleIdList><ArticleId IdType="pubmed">14760812</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini A, Ravelli A, Avcin T et al (2019) Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 46:190&#x2013;197. https://doi.org/10.3899/jrheum.180168</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180168</ArticleId><ArticleId IdType="pubmed">30275259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tappeiner C, Klotsche J, Sengler C et al (2018) Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study. Arthritis Rheumatol 70:1685&#x2013;1694. https://doi.org/10.1002/ART.40544/ABSTRACT</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.40544/ABSTRACT</ArticleId><ArticleId IdType="pubmed">29732713</ArticleId><ArticleId IdType="pmc">6174956</ArticleId></ArticleIdList></Reference><Reference><Citation>Storwick JA, Brett AC, Buhler K, Chin A, Schmeling H, Johnson NA, Fritzler MJ, Choi MY (2022) Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. Autoimmun Rev 21:103086. https://doi.org/10.1016/J.AUTREV.2022.103086</Citation></Reference><Reference><Citation>Gonz&#xe1;lez DA, de Le&#xf3;n AC, Varela AR, Garc&#xed;a MG, de Rahola M, S, P&#xe9;rez M del CR, Hern&#xe1;ndez AG, Falc&#xf3;n MJF, D&#xed;az BB (2011) Autoantibody detection with indirect immunofluorescence on HEp-2 cells: Starting serum dilutions for systemic rheumatic diseases. Immunol Lett 140:30&#x2013;35. https://doi.org/10.1016/J.IMLET.2011.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMLET.2011.06.001</ArticleId><ArticleId IdType="pubmed">21684306</ArticleId></ArticleIdList></Reference><Reference><Citation>Malleson PN, Sailer M, Mackinnon MJ (1997) Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 77:299&#x2013;304. https://doi.org/10.1136/adc.77.4.299</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.77.4.299</ArticleId><ArticleId IdType="pubmed">9389231</ArticleId><ArticleId IdType="pmc">1717342</ArticleId></ArticleIdList></Reference><Reference><Citation>McGhee JL, Kickingbird LM, Jarvis JN (2004) Clinical utility of antinuclear antibody tests in children. BMC Pediatr 4:1&#x2013;6. https://doi.org/10.1186/1471-2431-4-13/FIGURES/1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-4-13/FIGURES/1</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchten N, Hoyer A, Brinks R et al (2018) Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care Res 70:428&#x2013;438. https://doi.org/10.1002/ACR.23292/ABSTRACT</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACR.23292/ABSTRACT</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151&#x2013;1159. https://doi.org/10.1136/ANNRHEUMDIS-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ANNRHEUMDIS-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Floreani A, Leung PSC, Gershwin ME (2016) Environmental Basis of Autoimmunity. Clin Rev Allergy Immunol 50:287&#x2013;300. https://doi.org/10.1007/S12016-015-8493-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12016-015-8493-8</ArticleId><ArticleId IdType="pubmed">25998909</ArticleId></ArticleIdList></Reference><Reference><Citation>Marson A, Housley WJ, Hafler DA (2015) Genetic basis of autoimmunity. J Clin Invest 125:2234&#x2013;2241. https://doi.org/10.1172/JCI78086</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78086</ArticleId><ArticleId IdType="pubmed">26030227</ArticleId><ArticleId IdType="pmc">4497748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattalini M, Soliani M, Caparello MC (2017) Cimaz R (2017) Sex Differences in Pediatric Rheumatology. Clin Rev Allergy Immunol 563(56):293&#x2013;307. https://doi.org/10.1007/S12016-017-8642-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12016-017-8642-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan EKL, Damoiseaux J, Carballo OG et al (2015) Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) 2014&#x2013;2015. Front Immunol 6:412. https://doi.org/10.3389/FIMMU.2015.00412/BIBTEX</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2015.00412/BIBTEX</ArticleId><ArticleId IdType="pubmed">26347739</ArticleId><ArticleId IdType="pmc">4542633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P, Agrawal P, Verma RN et al (2021) Antinuclear Antibody Profiling in Patients of a Tertiary Care Centre in Central India. Indian J Clin Biochem 36(3):345&#x2013;352. https://doi.org/10.1007/s12291-020-00925-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-020-00925-2</ArticleId><ArticleId IdType="pubmed">34220010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan R, Jain D, Dorwal P, Roy G, Raina V, Nandi SP (2019) The incidence of immunofluorescence patterns and specific autoantibodies observed in autoimmune patients in a tertiary care centre. Eur Ann Allergy Clin Immunol 51:165&#x2013;173. https://doi.org/10.23822/EURANNACI.1764-1489.93</Citation></Reference><Reference><Citation>Rodsaward P, Chottawornsak N, Suwanchote S et al (2021) The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pac J Allergy Immunol 39(4):279&#x2013;286. https://doi.org/10.12932/AP-211218-0465</Citation></Reference><Reference><Citation>Urowitz MB, Gladman DD, Iba&#xf1;ez D et al (2012) Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 64:132&#x2013;137. https://doi.org/10.1002/ACR.20648</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACR.20648</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N, Damoiseaux J, Kallenberg C et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17&#x2013;23. https://doi.org/10.1136/annrheumdis-2013-203863</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203863</ArticleId><ArticleId IdType="pubmed">24126457</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>